Latest Breaking News On - Neuraxpharm pharmaceuticals - Page 1 : comparemela.com

Rare Disease Day 2024 - Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy

/PRNewswire/ Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS).

United statesComunidad autonoma de catalunaFrance generalKaren harrisonThomas dierksLaboratorios lesviFanny mochelMarc martinellNeuraxpharm pharmaceuticalsReference centerNeuraxpharm groupLeukodystrophy charityRoche venture fundPrnewswire neuraxpharm groupMinoryx therapeuticsRare disease day

Neuraxpharm: Rare Disease Day 2024 - Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy

Neuraxpharm: Rare Disease Day 2024 - Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaFrance generalUnited statesLaboratorios lesviFanny mochelThomas dierksKaren harrisonMarc martinellPrnewswire neuraxpharm groupNeuraxpharm groupLeukodystrophy charityRoche venture fundReference centerNeuraxpharm pharmaceuticalsMinoryx therapeuticsRare disease day

Rare Disease Day 2024 - Call For Greater Awareness Of X-Linked Adrenoleukodystrophy And Cerebral Adrenoleukodystrophy - Special Film Launched

Rare Disease Day 2024 - Call For Greater Awareness Of X-Linked Adrenoleukodystrophy And Cerebral Adrenoleukodystrophy - Special Film Launched
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalComunidad autonoma de catalunaLaboratorios lesviKaren harrisonThomas dierksMarc martinellFanny mochelLeukodystrophy charityNeuraxpharm groupRoche venture fundNeuraxpharm pharmaceuticalsReference centerPrnewswire neuraxpharm groupMinoryx therapeuticsRare disease day

Nezglyal remains promising therapy despite EMA s market authorization refusal

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently refused marketing authorization for Nezglyal (leriglitazone).

Aakash patelNeuraxpharm pharmaceuticalsMinoryx therapeuticsX linked adrenoleukodystrophyMarkets amp regulationsBio developmentsEmerging marketsMarketing authorizationEuropean medicines agency

Update on Regulatory Review of leriglitazone in the EU

Update on Regulatory Review of leriglitazone in the EU

Comunidad autonoma de catalunaUnited statesMarc martinellLaboratorios lesviMichelle boxallThomas dierksImage box communicationsStrategic communicationsNeuraxpharm pharmaceuticalsNeuraxpharm groupCommittee for medicinal products human useRoche venture fundMinoryx therapeuticsMedicinal productsHuman useHematopoietic stem cell transplantation